Media
View our latest materials to follow our progress in tackling respiratory diseases.
Latest Videos
View all videos
Filters
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
Paper demonstrates ensifentrine’s potential in improving lung function and quality of life symptoms
Holding(s) in Company TR-1: Standard form for notification of major holdings
LONDON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
Verona Pharma Announces Senior Management Changes
LONDON, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., has been appointed President and Chief Executive Officer (CEO) with effect from February 1, 2020.
Verona Pharma to Present at LSX World Congress 2020
LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO of Verona Pharma, will present a corporate overview and host one-on-one meetings at the LSX World Congress taking place in London on February 4-5, 2020.
Holding(s) in Company TR-1: Standard form for notification of major holdings
LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: Standard form for notification of major holdings
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function. Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality of life. Conference call scheduled for 6.00 am PST / 9.00 am EST / 2.00 pm GMT on Monday, January 13, 2020.
Verona Pharma
Investor Information
© Verona Pharma plc 2020. All rights reserved